Drug Price Transparency
The AHA today voiced support for a Centers for Medicare & Medicaid Services’ proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to “rein in skyrocketing drug prices” for patients and the providers who serve them.
The AHA voiced support for a Centers for Medicare & Medicaid Services’ proposal to require drug pricing transparency in direct-to-consumer television advertisements and encouraged the agency to “rein in skyrocketing drug prices” for patients and the providers who serve them. “We appreciate CMS’…
The Centers for Medicare & Medicaid Services today issued a proposed rule aimed at increasing drug price transparency and reducing the price of prescription drugs and biological products to consumers by requiring drug manufacturers to include list prices in all direct-to-consumer television…
The House of Representatives yesterday passed two bills that would prohibit health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance.
The Senate last night voted 98-2 to approve the Patient Right to Know Drug Prices Act (S. 2554), a bill that would prohibit private health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance.
A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and Manufacturers of America that incorrectly blame hospitals for the rising price of drugs.
AHA letter to the US Senate supporting Amendment #3787 to address ‘out-of-control cost’ of prescription drugs.
AHA comments on the 340B section of the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
AHA commends MedPAC and HHS for voicing significant concerns about rising pharmaceutical costs.